Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Xcell Therapeutics Inc. (373110:KRX), powered by AI.
Xcell Therapeutics Inc. is currently trading at ₩1,407. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Xcell Therapeutics Inc. on Alpha Lenz.
Xcell Therapeutics Inc.'s P/E ratio is -2.2.
“Xcell Therapeutics Inc. trades at a P/E of -2.2 (undervalued) with modest ROE of -134.4%. 3Y revenue CAGR of 24.1% highlights clear growth momentum.”
Ask for details →Xcell Therapeutics Inc. is a biotechnology company focused on the research and development of advanced therapeutic solutions. Operating at the cutting edge of biotechnology, the company’s primary aim is to develop innovative treatments that address unmet medical needs. Xcell Therapeutics Inc. specializes in regenerative medicine, leveraging stem cell technology to create therapies that have significant implications for treating a variety of chronic and degenerative diseases. This company plays a crucial role in the healthcare sector by offering potential solutions that could transform current treatment paradigms for conditions such as heart disease, neurological disorders, and other critical illnesses. By emphasizing precision medicine, Xcell Therapeutics Inc. impacts both medical research and clinical applications, contributing to more personalized and effective healthcare solutions. The company's efforts are significant in advancing the frontier of medical science, highlighting the growing importance of biotechnology firms in driving future healthcare innovations.
“Xcell Therapeutics Inc. trades at a P/E of -2.2 (undervalued) with modest ROE of -134.4%. 3Y revenue CAGR of 24.1% highlights clear growth momentum.”
Ask for details →Xcell Therapeutics Inc. (ticker: 373110) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 67 employees. Market cap is $24.3B.
The current price is ₩1,407 with a P/E ratio of -2.23x and P/B of 3.41x.
ROE is -134.41% and operating margin is -556.79%. Annual revenue is $1.9B.